[Pharmacogenomic data for personalized medicines].
FDA issued guidance for industry regarding pharmarcogenomic data submission this year. Polymorphic cytochrome P450 2D6 and thiopurine S-methyltransferase in patients are now considered biomarkers for drugs which are predominantly metabolized by these enzymes. This article reviews current efforts to treat pharmacogenomic data for new drug development and personalized medicines.